Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2009

01.01.2009 | Short Communication

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT

verfasst von: Matthias Miederer, Stefan Seidl, Andreas Buck, Klemens Scheidhauer, Hans-Jürgen Wester, Markus Schwaiger, Aurel Perren

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In clinical routine somatostatin analogue positron emission tomography/computed tomography (PET/CT) such as 68Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT could substitute conventional 111In-Octreotide scintigraphy. Immunohistochemistry (IHC) for somatostatin receptor 2 (SSTR2) might be a tool to predict positivity of 68Ga-DOTATOC in patients where initial staging was not performed, e.g., in incidental findings. We therefore compared a score of SSTR2-IHC with the in vivo standard uptake value (SUV) of preoperative or prebiopsy 68Ga-DOTATOC PET/CT.

Materials and methods

In 18 patients, 68Ga-DOTATOC PET/CT scans were quantified with SUV calculations and correlated to a cell membrane-based SSTR2-IHC score (ranging from 0 to 3).

Results

Negative IHC scores were consistent with SUV values below 10. Furthermore, all score 2 and 3 specimens corresponded with high SUV values (above 15).

Conclusion

SSTR2-IHC scores correlated well with SUV values and we propose to use SSTR2 immunohistochemistry in patients missing a preoperative PET scan to indicate 68Ga-DOTATOC-PET/CT as method for restaging and follow-up in individual patients.
Literatur
1.
Zurück zum Zitat Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, Pauwels S, Reubi JC. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 2005;46(Suppl 1):76S–82S.PubMed Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, Pauwels S, Reubi JC. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med 2005;46(Suppl 1):76S–82S.PubMed
2.
Zurück zum Zitat Kwekkeboom DJ, Krenning EP. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Eur Radiol 1997;7(7):1103–9.PubMedCrossRef Kwekkeboom DJ, Krenning EP. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Eur Radiol 1997;7(7):1103–9.PubMedCrossRef
3.
Zurück zum Zitat van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine 2003;20(3):307–11.PubMedCrossRef van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine 2003;20(3):307–11.PubMedCrossRef
4.
Zurück zum Zitat Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.PubMedCrossRef Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.PubMedCrossRef
5.
Zurück zum Zitat Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.PubMedCrossRef Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.PubMedCrossRef
6.
Zurück zum Zitat Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008;87(1):47–62.PubMedCrossRef Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008;87(1):47–62.PubMedCrossRef
7.
Zurück zum Zitat Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26.PubMedCrossRef Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26.PubMedCrossRef
8.
Zurück zum Zitat Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20(11):1172–82.PubMedCrossRef Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20(11):1172–82.PubMedCrossRef
9.
Zurück zum Zitat Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26(6):963–70.PubMedCrossRef Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26(6):963–70.PubMedCrossRef
10.
Zurück zum Zitat Wieder H, Beer AJ, Poethko T, Meisetschlaeger G, Wester HJ, Rummeny E, Schwaiger M, Stahl AR. PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. Eur J Nucl Med Mol Imaging 2008;35(2):264–71.PubMedCrossRef Wieder H, Beer AJ, Poethko T, Meisetschlaeger G, Wester HJ, Rummeny E, Schwaiger M, Stahl AR. PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. Eur J Nucl Med Mol Imaging 2008;35(2):264–71.PubMedCrossRef
Metadaten
Titel
Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT
verfasst von
Matthias Miederer
Stefan Seidl
Andreas Buck
Klemens Scheidhauer
Hans-Jürgen Wester
Markus Schwaiger
Aurel Perren
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0944-5

Weitere Artikel der Ausgabe 1/2009

European Journal of Nuclear Medicine and Molecular Imaging 1/2009 Zur Ausgabe